Inhibition of growth and motility of human A549 lung carcinoma cells by a recombined vascular basement membrane derived peptide

Cancer Letters

Volumn 292, Issue 2, 2010, Pages 261-268

  Wang, Cheng kun ^a,b   Cao, Jian guo ^c   Peng, Bo ^a   Gu, Yi xue ^a   Zheng, Guo pei ^a   He, Zhi min ^a  

^a Central South University   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Anti neoplastic mechanism; CDNA Microarray; Lung carcinoma; Polypeptide drug

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ALPHA4 INTEGRIN; ALPHA6 INTEGRIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; CD146 ANTIGEN; CD51 ANTIGEN; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBROBLAST GROWTH FACTOR 2; GENE PRODUCT; GRANZYME A; HERMES ANTIGEN; METASTIN; PLATELET DERIVED GROWTH FACTOR B; PROTEIN BAX; PROTEIN BCL 2; PROTEIN RAF1; PROTEIN RASA1; PROTEIN TYROSINE KINASE; RECOMBINED VASCULAR BASEMENT MEMBRANE DERIVED MULTIFUNCTIONAL PEPTIDE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR; PEPTIDE; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SCREENING; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC IDENTIFICATION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUNG CARCINOMA; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THERAPY EFFECT; UPREGULATION; WESTERN BLOTTING; BASEMENT MEMBRANE; CANCER INVASION; CELL DIVISION; CELL MOTION; CHEMISTRY; DRUG EFFECT; IMMUNOPRECIPITATION; LUNG TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BASEMENT MEMBRANE; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PEPTIDES; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS;

EID: 77951934085     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.12.010     Document Type: Article

References (45)

1. William W.N., Lin H.Y., Lee J.J., Lippman S.M., Roth J.A., Kim E.S. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009, 136:701-709.
2. Shahan T.A., Ziaie Z., Pasco S., et al. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res. 1999, 59:4584-4590.
3. Maeshima Y., Colorado P.C., Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 2000, 275:23745-23750.
4. Maeshima Y., Colorado P.C., Torre A., et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 2000, 275:21340-21348.
5. Peng S.P., Fang W.Y., Dai W.J., et al. Expression and space conformation analysis of vascular basement membrane-derived multifunctional peptide. Chin. J. Cancer Biother. 2003, 185-189.
6. Cao J.G., Peng S.P., Sun L., Li H., Wang L., Deng H.W. Vascular basement membrane-derived multifunctional peptide, a novel inhibitor of angiogenesis and tumor growth. Acta Biochim. Biophys. Sin. (Shanghai) 2006, 38:514-521.
7. Peng S.P., Fang W.Y., Jiang R.C., Zou J.G., Dong L., Cao J.G. Prokaryotic expression of vascular basement membrane-derived multifunctional peptide and its anti-tumor activity assay. Chin. Pharmacol. Bull. 2003, 678-682.
8. Li H., Cao J.G., Sun L., Wang L., Dong L., Zhou J.G. Vascular basement membrane derived multifunctional peptide selectively inhibits proliferation of lung cancer cells. J. Hunan Normal Univ. (Med. Sci.) 2006, 1-6 and 10. Cnki:ISSN:1673-016X.0.2006-01-001.
9. Abdollahi A., Hahnfeldt P., Maercker C., et al. Endostatin's antiangiogenic signaling network. Mol. Cell 2004, 13:649-663.
10. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 2003, 100:4766-4771.
11. Chiang A.C., Massague J. Molecular basis of metastasis. N. Engl. J. Med. 2008, 359:2814-2823.
12. Liu W., Ahmad S.A., Reinmuth N., et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000, 5:323-328.
13. Sweeney C.J., Miller K.D., Sissons S.E., et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61:3369-3372.
14. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
15. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
16. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo. Clin. Proc. 2008, 83:584-594.
17. Skrickova J., Coupek P., Babickova L., et al. Treatment of non small cell lung cancer. Klin Onkol. 2008, 21:317-329.
18. Sorensen M., Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009, 20(Suppl. 4):71-72.
19. West H.J. Novel targeted agents for lung cancer. Clin. Lung Cancer 2009, 10(Suppl. 1):S41-46.
20. Giard D.J., Aaronson S.A., Todaro G.J., et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 1973, 51:1417-1423.
21. Sung J.M., Cho H.J., Yi H., et al. Characterization of a stem cell population in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 2008, 371:163-167.
22. Maeshima Y., Yerramalla U.L., Dhanabal M., et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 2001, 276:31959-31968.
23. Maeshima Y., Manfredi M., Reimer C., et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 2001, 276:15240-15248.
24. Reynolds L.E., Wyder L., Lively J.C., et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 2002, 8:27-34.
25. Hamano Y., Zeisberg M., Sugimoto H., et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
26. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr. Opin. Cell Biol. 1997, 9:701-706.
27. Blystone S.D., Williams M.P., Slater S.E., Brown E.J. Requirement of integrin beta3 tyrosine 747 for beta3 tyrosine phosphorylation and regulation of alphavbeta3 avidity. J. Biol. Chem. 1997, 272:28757-28761.
28. Butler B., Williams M.P., Blystone S.D. Ligand-dependent activation of integrin alpha vbeta 3. J. Biol. Chem. 2003, 278:5264-5270.
29. Zajac-Kaye M. Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung Cancer 2001, 34(Suppl. 2):S43-S46.
30. Karamouzis M.V., Papavassiliou A.G. The IGF-1 network in lung carcinoma therapeutics. Trends Mol. Med. 2006, 12:595-602.
31. Fischer H., Taylor N., Allerstorfer S., et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol. Cancer Ther. 2008, 7:3408-3419.
32. Choi U.J., Jee B.K., Lim Y., Lee K.H. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells. Cell Biochem. Funct. 2009, 27:40-47.
33. Nash K.T., Welch D.R. The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front. Biosci. 2006, 11:647-659.
34. Peng P.L., Hsieh Y.S., Wang C.J., Hsu J.L., Chou F.P. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol. Appl. Pharmacol. 2006, 214:8-15.
35. Dass K., Ahmad A., Azmi A.S., Sarkar S.H., Sarkar F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 2008, 34:122-136.
36. Galaktionov K., Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991, 67:1181-1194.
37. Sadhu K., Reed S.I., Richardson H., Russell P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA 1990, 87:5139-5143.
38. Kiyokawa H., Ray D. In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med. Chem. 2008, 8:832-836.
39. Kar S., Wang M., Carr B.I. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother. Pharmacol. 2008, 62:831-840.
40. Wu W., Fan Y.H., Kemp B.L., Walsh G., Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998, 58:4082-4085.
41. Wrage M., Ruosaari S., Eijk P.P., et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin. Cancer Res. 2009, 15:1566-1574.
42. Ho J., Kong J.W., Choong L.Y., et al. Novel breast cancer metastasis-associated proteins. J. Proteome Res. 2009, 8:583-594.
43. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72:1-22.
44. McMahon B., Kwaan H.C. The plasminogen activator system and cancer. Pathophysiol. Haemost. Thromb. 2008, 36:184-194.
45. Sheng S. The feasibility of uPA/uPAR-targeting strategies in cancer treatment. Cancer Biol. Ther. 2008, 7:660-662.